WEKO3
アイテム
骨軟部悪性腫瘍重粒子線治療におけるC-11 methionine PETの有用性の研究
https://repo.qst.go.jp/records/55375
https://repo.qst.go.jp/records/55375de653b3f-579d-4105-a7f7-5f2ba2603ed9
| Item type | 一般雑誌記事 / Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2005-02-25 | |||||
| タイトル | ||||||
| タイトル | 骨軟部悪性腫瘍重粒子線治療におけるC-11 methionine PETの有用性の研究 | |||||
| 言語 | ||||||
| 言語 | jpn | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
吉川, 京燦
× 吉川, 京燦× 張, 宏× 佐合, 賢治× 石川, 博之× 田村, 克巳× 松野, 典代× 神立, 進× 鎌田, 正× 須原, 哲也× 鈴木, 和年× 辻井, 博彦× 吉川 京燦× 張 宏× 佐合 賢治× 石川 博之× 田村 克巳× 松野 典代× 神立 進× 鎌田 正× 須原 哲也× 鈴木 和年× 辻井 博彦 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Purpose: The development of the novel carbon ion radiotherapy (CIRT) in the treatment of refractory cancers has resulted in the need for a way to accurately evaluate patients'prognosis. We evaluated whether 11C-methionine (MET) uptake and its change after CIRT were the early survival factors in patients with unresectable bone and soft tissue sarcomas. Patients and Methods: MET PET was prospectively performed in 62 patients with unresectable bone and soft tissue sarcomas before and within one month after CIRT. Tumor MET uptake was measured with the semiquantitative tumor-to-nontumor- ratio (T/N ratio). The MET uptake in the tumor and relevant clinical parameters were entered into univariate and multivarite survival analysis. Results: The overall median survival time was 20 months. Patients with a baseline T/N ratio of < 6 had a significant better survival than patients with a baseline T/N ratio > 6 (2-year survival rate: 69.4% versus 32.3%, P=0.01). Patients with a post CIRT ratio of < 4.4 had a better survival than that with a post CIRT ratio > 4.4 (2-year survival rate: 63.7% versus 41.3%, P=0.01). A significant higher survival rate was observed in patients with posttherapeutic MET uptake change of > 30% than patients in lower change group (2-year survival rate: 74.6%, P=0.049). The multivariate analysis showed that both baseline and post CIRT T/N ratio were statistically significant independent predictors of patient survival. Tumors with larger T/N ratio had a significantly poorer prognosis. Conclusions: MET uptake, as measured by either baseline or post CIRT T/N ratio was an independent predictor of survival in patients with bone and soft tissue sarcomas treated by carbon ion radiotherapy, while posttherapeutic MET uptake change might have potential value for the same purpose. |
|||||
| 書誌情報 |
放射線医学総合研究所重粒子線がん治療装置等共同利用研究報告書 p. 39-40, 発行日 2004-05 |
|||||
| 出版者 | ||||||
| 出版者 | 放医研 | |||||
